Discovering the Antecedents of Rheumatoid Arthritis Flare

April 15, 2026 updated by: Rockefeller University
Longitudinal study of patients with rheumatoid arthritis comparing measures of disease activity with blood samples.

Study Overview

Status

Active, not recruiting

Conditions

Detailed Description

80% of patients living with rheumatoid arthritis can expect fluctuations in their symptoms over time. Dramatic increases in disease activity are considered flare. This study will follow patients with increased risk for flare prospectively for one year. Serial questionnaires and disease activity scores will be compared to blood samples to better understand the molecular phenotype of rheumatoid arthritis flares.

Study Type

Observational

Enrollment (Estimated)

25

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • New York
      • New York, New York, United States, 10065
        • The Rockefeller University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Rheumatoid Arthritis

Description

Inclusion Criteria:

  • 2010 criteria for Rheumatoid Arthritis
  • Swelling of at least one joint and or elevated acute phase reactants
  • Greater than or equal to 40 years old or less than or equal to 65 year old female sex
  • cyclic citrullinated peptide antibody + in the past 12 months

Exclusion Criteria:

  • hemoglobin < 9
  • white blood cell count < 3.5
  • Diagnosis of any active malignancy within the last 3 years besides non-melanomatous skin cancer
  • Diagnosis of diabetes and requires insulin
  • HIV+, Hep B S Ag+, Hep C polymerase chain reaction +
  • Untreated latent tuberculosis
  • Diagnosis of any additional systemic autoimmune connective tissue disease
  • Inability to reliably complete study requirements
  • History, physical, social or laboratory findings suggestive of any other medical or psychological condition that would, in the opinion of the principal investigator, make the candidate ineligible for the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
RNA transcripts that correlate with rheumatoid arthritis disease activity
Time Frame: 1 year
Blood drawn at various times throughout one year will be correlated with fluctuations in RA disease activity.
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Rockefeller University

Investigators

  • Principal Investigator: Dana E Orange, MD, MS, The Rockefeller University Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

February 1, 2014

Primary Completion (Estimated)

February 1, 2030

Study Completion (Estimated)

February 1, 2030

Study Registration Dates

First Submitted

January 29, 2014

First Submitted That Met QC Criteria

January 29, 2014

First Posted (Estimated)

January 31, 2014

Study Record Updates

Last Update Posted (Actual)

April 16, 2026

Last Update Submitted That Met QC Criteria

April 15, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • DOR-0833

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Rheumatoid Arthritis

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Panama

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe